Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q32 BioQTTB -1.59%17 14-Day RSI is 53.94 as of Jul. 27, 2026. GuruFocus rates QTTB with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 1,423 Biotechnology companies, Q32 Bio ranks worse than 82.43% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-27), Q32 Bio's 14-Day RSI is 53.94.
The industry rank for Q32 Bio's 14-Day RSI or its related term are showing as below:
QTTB's 14-Day RSI is ranked worse than 82.43% of 1423
companies
in the Biotechnology industry
Industry Median: 44.14
vs QTTB: 53.94
Q32 Bio (NAS:QTTB) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Q32 Bio 14-Day RSI Related Terms
QTTB vs KYTX, PRTA, CABA: 14-Day RSI Comparison
For the Biotechnology subindustry, Q32 Bio's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q32 Bio 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Q32 Bio's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Q32 Bio's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q32 Bio (QTTB) has a 14-Day RSI of 53.94 as of Jul. 27, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Q32 Bio and its competitors. According to the industry distribution chart, Q32 Bio ranks #1173 out of 1423 companies in the Biotechnology industry, placing it in the top 82.4%.
Is Q32 Bio's 14-Day RSI too high?
Q32 Bio's current 14-Day RSI is 53.94. The Biotechnology industry median 14-Day RSI is 44.14. Q32 Bio's value of 53.94 is 22.2% above this industry median. Based on the distribution chart, Q32 Bio ranks #1173 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's 14-Day RSI compare to KYTX and PRTA?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #1173 out of 1423 companies for 14-Day RSI. This places Q32 Bio in the lower half of its industry. The industry median 14-Day RSI is 44.14. Q32 Bio's value of 53.94 is 22.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 44.14, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q32 Bio's current 14-Day RSI of 53.94 is 22.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Q32 Bio and its competitors. For the Biotechnology industry, the median 14-Day RSI is 44.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q32 Bio's current 14-Day RSI is 53.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (QTTB) has a current 14-Day RSI of 53.94. The current 14-Day RSI is 53.94 and 22.2% above the Biotechnology industry median of 44.14. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Q32 Bio (QTTB), the current 14-Day RSI is 53.94 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score
Get the complete analysis for QTTB
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QTTB has been successfully added to your 
